MA31204B1 - Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes - Google Patents

Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes

Info

Publication number
MA31204B1
MA31204B1 MA32191A MA32191A MA31204B1 MA 31204 B1 MA31204 B1 MA 31204B1 MA 32191 A MA32191 A MA 32191A MA 32191 A MA32191 A MA 32191A MA 31204 B1 MA31204 B1 MA 31204B1
Authority
MA
Morocco
Prior art keywords
phenyl
forms
polymorphs
morpholin
isoxazole
Prior art date
Application number
MA32191A
Other languages
Arabic (ar)
English (en)
Inventor
Martin James Drysdale
Brian William Dymock
Christoph Krell
Michael Mutz
Holger Petersen
Weijia Zheng
Original Assignee
Novartis Ag
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31204(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Vernalis R&D Ltd filed Critical Novartis Ag
Publication of MA31204B1 publication Critical patent/MA31204B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouvelles formes de sels d'éthylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique, en particulier leur sel mésylate, chlorhydrate, tartrate, phosphate et hémifumarate; des formes cristallines de ces sels; des polymorphes d'éthylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique; des hydrates et des polymorphes de ces nouvelles formes de sels décrites ci-dessus; l'utilisation de ces nouvelles formes de sels décrites ci-dessus pour la mise au point d'un médicament destiné au traitement d'un trouble induit par la hsp90; une méthode de traitement d'un trouble induit par la hsp90 dans laquelle ces nouvelles formes de sels sont utilisées; des préparations comprenant ces formes de sels, en particulier des solutions aqueuses pouvant être administrées par voie intraveineuse; ainsi que des contenants en verre ambré remplis avec ces préparations.
MA32191A 2007-03-01 2009-08-31 Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes MA31204B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01
PCT/EP2008/052443 WO2008104595A1 (fr) 2007-03-01 2008-02-28 Sels d'addition acides, hydrates et polymorphes d'éthylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique et préparations comprenant ces formes

Publications (1)

Publication Number Publication Date
MA31204B1 true MA31204B1 (fr) 2010-02-01

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32191A MA31204B1 (fr) 2007-03-01 2009-08-31 Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes

Country Status (41)

Country Link
US (3) US8163747B2 (fr)
EP (2) EP2131845B1 (fr)
JP (1) JP2010520176A (fr)
KR (1) KR20090122218A (fr)
CN (2) CN101636162A (fr)
AR (1) AR065519A1 (fr)
AT (1) ATE552836T1 (fr)
AU (1) AU2008220800B2 (fr)
BR (1) BRPI0807992A2 (fr)
CA (1) CA2678043A1 (fr)
CL (1) CL2008000618A1 (fr)
CO (1) CO6210828A2 (fr)
CR (1) CR10989A (fr)
CY (1) CY1113805T1 (fr)
DK (1) DK2131845T3 (fr)
DO (1) DOP2009000209A (fr)
EA (1) EA017075B1 (fr)
EC (1) ECSP099602A (fr)
ES (1) ES2384906T3 (fr)
GE (1) GEP20115309B (fr)
GT (1) GT200900236A (fr)
HK (1) HK1139073A1 (fr)
HR (1) HRP20120535T1 (fr)
IL (1) IL200401A0 (fr)
MA (1) MA31204B1 (fr)
MX (1) MX2009009233A (fr)
NI (1) NI200900161A (fr)
NZ (1) NZ578854A (fr)
PA (1) PA8771101A1 (fr)
PE (1) PE20090166A1 (fr)
PL (1) PL2131845T3 (fr)
PT (1) PT2131845E (fr)
RS (1) RS52351B (fr)
SI (1) SI2131845T1 (fr)
SM (1) SMAP200900080A (fr)
TN (1) TN2009000357A1 (fr)
TW (1) TW200844102A (fr)
UA (1) UA101950C2 (fr)
UY (1) UY30943A1 (fr)
WO (1) WO2008104595A1 (fr)
ZA (1) ZA200905417B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
US8309578B2 (en) 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
AU2011208681B2 (en) * 2010-01-21 2014-10-23 Aprea Therapeutics Ab Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
CN102753546A (zh) * 2010-02-17 2012-10-24 日东制药株式会社 新型5-元杂环衍生物及其制备方法
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (fr) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Nouveaux promédicaments de 5-(2,4-dihydroxy-5-isopropylphényl)-n-éthyl-4-(5-méthyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407403B1 (pt) 2003-02-11 2022-07-19 Cancer Research Technology Ltd Compostos de isoxazol e composição farmacêutica
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
MX2009008584A (es) 2007-02-15 2009-08-18 Novartis Ag Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.
WO2010069458A1 (fr) 2008-12-17 2010-06-24 Merck Patent Gmbh Complexes d'hexahalochromate (iii)

Also Published As

Publication number Publication date
ECSP099602A (es) 2009-12-28
DK2131845T3 (da) 2012-07-16
CL2008000618A1 (es) 2008-09-12
NI200900161A (es) 2010-07-27
UA101950C2 (ru) 2013-05-27
PL2131845T3 (pl) 2012-09-28
TN2009000357A1 (en) 2010-12-31
CR10989A (es) 2010-03-01
PA8771101A1 (es) 2009-02-09
EP2131845B1 (fr) 2012-04-11
AR065519A1 (es) 2009-06-10
EA017075B1 (ru) 2012-09-28
ZA200905417B (en) 2010-05-26
US8163747B2 (en) 2012-04-24
MX2009009233A (es) 2010-06-02
PE20090166A1 (es) 2009-03-14
EP2545921A2 (fr) 2013-01-16
BRPI0807992A2 (pt) 2014-06-17
GT200900236A (es) 2011-09-14
CO6210828A2 (es) 2010-10-20
US8487095B2 (en) 2013-07-16
CA2678043A1 (fr) 2008-09-04
TW200844102A (en) 2008-11-16
GEP20115309B (en) 2011-10-25
EP2131845A1 (fr) 2009-12-16
ATE552836T1 (de) 2012-04-15
HK1139073A1 (fr) 2010-09-10
AU2008220800A1 (en) 2008-09-04
JP2010520176A (ja) 2010-06-10
US20130296556A1 (en) 2013-11-07
KR20090122218A (ko) 2009-11-26
RS52351B (en) 2012-12-31
AU2008220800B2 (en) 2012-02-16
EA200901141A1 (ru) 2010-04-30
UY30943A1 (es) 2008-10-31
SI2131845T1 (sl) 2013-02-28
US20100093732A1 (en) 2010-04-15
SMAP200900080A (it) 2010-01-19
EP2545921A3 (fr) 2013-04-10
NZ578854A (en) 2012-03-30
US20120172592A1 (en) 2012-07-05
WO2008104595A1 (fr) 2008-09-04
IL200401A0 (en) 2010-04-29
CN101636162A (zh) 2010-01-27
PT2131845E (pt) 2012-07-10
HRP20120535T1 (hr) 2012-07-31
ES2384906T3 (es) 2012-07-13
CY1113805T1 (el) 2016-07-27
DOP2009000209A (es) 2009-09-15
CN102302500A (zh) 2012-01-04

Similar Documents

Publication Publication Date Title
MA31204B1 (fr) Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes
PH12019501707A1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
MA42292B1 (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
BRPI0612072A2 (pt) inibidores da aspartil protease
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
MA35090B1 (fr) Polythérapie pour les malignités hématologiques
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA31373B1 (fr) Composes amino-heterocycliques
NO20071314L (no) Peptidiske vasopressinreseptoragonister
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
MA30576B1 (fr) Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
MA31684B1 (fr) Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation
NZ710574A (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors